Effects of sacubitril/valsartan on cardiac calcineurin /nuclear factor of activated T cell-3 signaling pathway in myocardium of spontaneously hypertensive rats
- Author:
- No author available
- Journal Title:
- China Medicine
- Issue:
- 12
- DOI:
- 10.3760/j.issn.1673-4777.2022.12.005
- Key Word:
- 自发性高血压大鼠;心肌纤维化;沙库巴曲缬沙坦;钙调神经磷酸酶;活化T细胞核因子3
Abstract： 目的 探讨沙库巴曲缬沙坦对自发性高血压大鼠(SHR)心肌钙调神经磷酸酶/活化T细胞核因子3(CaN/NFAT3)信号通路的影响.方法 选择16只16周龄雄性SHR完全随机分为模型组(8只)和治疗组(8只),选择相同周龄的8只血压正常的Wistar-Kyoto大鼠作为对照组.治疗组大鼠给予沙库巴曲缬沙坦65 mg/kg,对照组和模型组大鼠给予等容积0.9％氯化钠溶液,均每天1次灌胃,连续4周.干预4周后,超声心动图检测各组大鼠心脏舒张期室间隔厚度(IVSd)和左心室舒张期后壁厚度(LVPWd);组织病理学评估心肌细胞形态及心肌纤维化程度;免疫组织化学染色和蛋白质印迹法检测心肌组织CaN和NFAT3蛋白表达情况.结果 干预后,模型组大鼠IVSd、LVPWd均高于对照组[(2.53±0.35)mm比(1.28±0.14)mm、(2.32±0.29)mm比(1.31±0.12)mm],而治疗组大鼠IVSd、LVPWd[(2.02±0.15)mm、(1.85±0.14)mm]均低于模型组(均P<0.01).模型组心肌细胞横截面积和心肌胶原纤维百分比均明显高于对照组,而治疗组心肌细胞横截面积和心肌胶原纤维百分比均低于模型组(均P<0.01).免疫组织化学染色结果 显示,模型组心肌组织CaN蛋白表达水平高于对照组,治疗组CaN蛋白表达水平低于模型组(均P<0.01).蛋白质印迹法检测结果 显示,模型组CaN蛋白和NFAT3蛋白表达水平均高于对照组[(0.95±0.05)比(0.55±0.05)、(0.84±0.04)比(0.53±0.05)],而治疗组CaN蛋白和NFAT3蛋白表达水平[(0.65±0.05)、(0.65±0.03)]均低于模型组(均P<0.01).结论 沙库巴曲缬沙坦能够减轻SHR心肌纤维化及抑制心肌肥厚,其作用机制可能与抑制CaN/NFAT3信号通路有关.
- [1]王雪婷,罗明.粒细胞集落刺激因子对自发性高血压大鼠心室重构的调控[J].2014,(2).
- [2]李映红,欧阳静萍,魏劲波.钙调神经磷酸酶在心血管系统中的作用[J].2003,(5).
- [3]索娅.ARNi对心肌肥厚射血分数保留性心衰的作用及机制研究[D].2018.
- [4]Flack, John M.,Adekola, Bemi.Blood pressure and the new ACC/AHA hypertension guidelines[J].2020,30(3).
- [5]Jeffery D Molkentin,Jian-Rong Lu,Christopher L Antos,etc.A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy[J].1998,93(2).
- [6]Wang, Jing,Wang, Yibing,Zhang, Wei,etc.Phenylephrine promotes cardiac fibroblast proliferation through calcineurin-NFAT pathway[J].2016,21(3).
- [7]DeVore, Adam D.,Braunwald, Eugene,Morrow, David A.,etc.Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial[J].2020,5(2).
- [8]Kompa, Andrew R.,Lu, Jiayu,Weller, Thomas J.,etc.Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction[J].2018,258.
- [9]Kumar, Santosh,Wang, Gang,Liu, Wenjuan,etc.Hypoxia-Induced Mitogenic Factor Promotes Cardiac Hypertrophy via Calcium-Dependent and Hypoxia-Inducible Factor-1 Mechanisms[J].2018,72(2).
- [10]Dierck, Franziska,Kuhn, Christian,Rohr, Claudia,etc.The novel cardiac z-disc protein CEFIP regulates cardiomyocyte hypertrophy by modulating calcineurin signaling[J].2017,292(37).
- [11]Moe, Gordon W.,Ezekowitz, Justin A.,O'Meara, Eileen,etc.The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications[J].2015,31(1).
- [12]Bueno O. F.,Wilkins B. J.,Tymitz K. M.,etc.Impaired cardiac hypertrophic response in Calcineurin A\u00a0-deficient mice[J].2002.
- [13]Le V,Rotter D,Backs J,etc.Reversibility of adverse, calcineurin-dependent cardiac remodeling.[J].2011,109(4).
- [14]Gu J,Noe A,Chandra P,etc.Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).[J].2010,50(4).
- [15]Andersen, Stine,Axelsen, Julie Birkmose,Ringgaard, Steffen,etc.Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure[J].2019,293.
- [16]中国医疗保健国际交流促进会高血压分会,中国医师协会心血管分会,中国高血压联盟,等.沙库巴曲缬沙坦在高血压患者临床应用的中国专家建议[J].2021,(2).
- [17]Liu Chung-Jung,Cheng Yi-Chang,Lee Kung-Wei,etc.Lipopolysaccharide induces cellular hypertrophy through calcineurin/NFAT-3 signaling pathway in H9c2 myocardiac cells[J].2008,313(1-2).